"immune checkpoint inhibitors therapy" trang 6 - tải miễn phí từ tailieunhanh
Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immunerelated adverse events of nivolumab: A case report

Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immunerelated adverse events of nivolumab: A case report
6    97    0
Anti-PD-1 antibody decreases tumourinfiltrating regulatory T cells

Anti-PD-1 antibody decreases tumourinfiltrating regulatory T cells
10    37    0
Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer

Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer
10    50    0
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
9    81    0
PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas

PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas
12    50    0
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
8    78    0
Intracranial antitumor responses of nivolumab and ipilimumab: A pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

Intracranial antitumor responses of nivolumab and ipilimumab: A pharmacodynamic and pharmacokinetic perspective, a scoping systematic review
8    45    0
Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer
11    45    1
Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: The first report

Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: The first report
4    38    1
Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: A case report

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: A case report
7    84    1
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
9    87    1
Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care

Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care
12    39    1
Clinical decision making in the era of immunotherapy for high grade-glioma: Report of four cases

Clinical decision making in the era of immunotherapy for high grade-glioma: Report of four cases
9    78    1
A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer
8    62    1
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
6    36    1
Immunotherapy for non-small cell lung cancers: Biomarkers for predicting responses and strategies to overcome resistance

Immunotherapy for non-small cell lung cancers: Biomarkers for predicting responses and strategies to overcome resistance
10    50    1
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
10    78    1
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: Study protocol of the TRADE-hypo trial

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: Study protocol of the TRADE-hypo trial
10    43    1
Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: Conformational changes of the BCloop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab

Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: Conformational changes of the BCloop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab
12    22    1
Response to pembrolizumab in a patient with primary lung adenocarcinoma originated from indium lung

Response to pembrolizumab in a patient with primary lung adenocarcinoma originated from indium lung
5    31    1